Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Conditions
Interventions
no-CIPN group:None
CIPN group:None
Sponsors
Zhongshan Hospital Affiliated to Xiamen University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=18 years. 2.Patients with a confirmed diagnosis of malignant tumor (any type or stage) who received chemotherapy containing platinum agents, taxanes, or their combination, excluding those in the palliative care phase. 3.Patients without pre-existing peripheral neuropathy symptoms (such as numbness, pain, or tingling) prior to chemotherapy and who were treated with platinum-based agents, taxanes, or their combination. 4.Voluntarily join this study, sign the informed consent form, and have good compliance.
Exclusion criteria
Exclusion criteria: 1.Peripheral neuropathy symptoms were already present prior to the first chemotherapy cycle. 2.Use of any non-chemotherapeutic drugs with potential neurotoxicity during the chemotherapy period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity and reliability of the risk prediction model for CIPN; | — |
Secondary
| Measure | Time frame |
|---|---|
| CIPN prevalence;Time window for patients to develop CIPN after chemotherapy, types of chemotherapeutic drugs, and cumulative drug dose;Effectiveness of PRO-CTCAE scoring, DN4 pain characteristic assessment scale, EORTC QLQ-CIPN20 scoring, and NRS pain scoring in distinguishing the severity of the condition; | — |
Countries
China
Contacts
Public ContactLi Xiao
Zhongshan Hospital Affiliated to Xiamen University
Outcome results
None listed